ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 226 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $56,476 | -86.4% | 1,219 | -87.8% | 0.00% | -100.0% |
| Q3 2022 | $414,000 | +29.4% | 10,000 | +181.5% | 0.00% | 0.0% |
| Q3 2021 | $320,000 | -39.0% | 3,553 | -23.0% | 0.00% | -66.7% |
| Q1 2021 | $525,000 | -59.0% | 4,612 | -50.2% | 0.00% | -57.1% |
| Q4 2020 | $1,282,000 | +282.7% | 9,258 | +18.3% | 0.01% | +250.0% |
| Q3 2019 | $335,000 | -59.9% | 7,823 | -35.0% | 0.00% | -66.7% |
| Q1 2019 | $835,000 | +31.1% | 12,034 | -17.8% | 0.01% | +20.0% |
| Q4 2018 | $637,000 | +46.1% | 14,648 | +55.8% | 0.01% | +400.0% |
| Q4 2017 | $436,000 | -8.8% | 9,400 | +22.1% | 0.00% | -50.0% |
| Q2 2017 | $478,000 | +38.2% | 7,700 | +51.0% | 0.00% | 0.0% |
| Q1 2017 | $346,000 | +49.1% | 5,100 | +54.5% | 0.00% | +100.0% |
| Q4 2016 | $232,000 | -95.3% | 3,300 | -92.5% | 0.00% | -97.1% |
| Q4 2015 | $4,908,000 | +20.7% | 43,750 | +3.6% | 0.03% | +13.3% |
| Q3 2015 | $4,066,000 | +32.4% | 42,216 | +40.7% | 0.03% | +57.9% |
| Q2 2015 | $3,072,000 | – | 30,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |